Abstract
Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Drug Approval
-
Fibrinolysin / administration & dosage
-
Fibrinolysin / metabolism
-
Fibrinolysin / pharmacology*
-
Fibrinolysin / therapeutic use*
-
Humans
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / pharmacology*
-
Peptide Fragments / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Retinal Diseases / drug therapy*
-
Retinal Diseases / pathology
-
Vitreous Body / drug effects*
-
Vitreous Body / pathology*
-
Vitreous Body / surgery
Substances
-
Peptide Fragments
-
microplasmin
-
Fibrinolysin